AI Might Find the Molecule, but Delivery Decides Whether it Becomes a Medicine

In this article, AustinPx Chief Scientific Officer Dave Miller examines how the rapid expansion of AI-enabled drug discovery is reshaping the pharmaceutical pipeline. While advanced computational tools can now identify and optimize candidate molecules at unprecedented speed, many of these compounds present significant challenges once they transition from virtual design into experimental development. Issues such as poor solubility, stability limitations, and manufacturability constraints often determine whether a promising molecule can realistically advance. Dave explores the growing gap between discovery speed and development readiness, and explains why early evaluation of deliverability, formulation strategy, and scalability is becoming increasingly important. As AI continues to expand the boundaries of chemical space, success will depend on development strategies that can translate promising molecules into viable, manufacturable medicines.